MODIFICATION
65 -- Pharmaceuticals
- Notice Date
- 4/7/2004
- Notice Type
- Modification
- NAICS
- 424210
— Drugs and Druggists' Sundries Merchant Wholesalers
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 10401 Fernwood Drive, Suite 2NE70, MSC 4811, Bethesda, MD, 20817
- ZIP Code
- 20817
- Solicitation Number
- NIAID-OCR-04-64
- Point of Contact
- Terrie Nestor, Contract Specialist, Phone 301-402-6790, Fax 301-480-0689,
- E-Mail Address
-
tnestor@niaid.nih.gov
- Description
- ****Due to formatting inconsistencies, the registered trademark symbols were converted to question marks. Please note that the question marks after the brand names of the requested pharmaceuticals indicate that they are registered trademarks.**** The National Institute of Allergy and Infectious Diseases (NIAID), Acquisitions Management and Operations Branch (AMOB) has an unrestricted requirement for pharmaceutical distribution within South Africa. NIAID intends to award a one year contract with the option for four additional years beginning on or before August 1, 2004. The resulting contract will also contain the provision at FAR 52.217-8. The contractor will be responsible for providing the antiretroviral drugs (ARV) identified below to the South African National Defense Force (SANDF) pharmacy depot upon receipt of individual delivery orders. All ARVs are brand name specific, identified by a manufacturer's commercial item description, and conform to the manufacturer's commercial specifications. Offerors must demonstrate that they have an established and ongoing contractual relationship and are in good standing with the manufacturers of the antiretroviral drugs; they have adequate storage space and optimal storage conditions to maintain the antiretroviral drugs from the time of receipt from the manufacturer to delivery to SANDF depot; they have the infrastructure to fulfill the order placement, delivery, and invoice requirements as outlined in the Statement of Work and can do so in a timely manner; and they are able to comply with the distribution requirements of the Medicines Control Council (MCC) of South Africa. The required ARVs are as follows: Didanosine (Videx?, Videx EC?, Bristol-Myers Squibb) - various dosages and formulations; Efavirenz (Stocrin?, MSD) - 200mg capsules, 50mg capsules; Lamivudine (Epivir? or 3TC?, Glaxo Smith Kline) - 150mg tablet or oral solution; Lopinavir/ritonavir (Kaletra?, Abbott) - 133mg/33mg capsules, oral liquid formulation; Nevirapine (Viramune?, Boehringer-Ingelheim) - 200mg capsules, 50mg/5mL suspension; Stavudine (Zerit?, Bristol-Myers Squibb) - 40mg, 30mg, 20mg capsules and 1mg/mL oral solution; Zidovudine (Retrovir?, Glaxo Smith Kline) - 300mg tablets, 100mg capsules, and oral syrup. Substitutions or changes to the identified ARVs may be required over the life of the contract. The solicitation may result in multiple awards. The NIAID intends to award a commercial item, FFP/EPA contract(s). The solicitation will be available for download on or around April 14, 2004 at www.fedbizopps.gov. Hard copies of the solicitation will not be distributed. Please refer any questions in writing to Terrie Nestor at tnestor@niaid.nih.gov.
- Place of Performance
- Address: South Africa
- Record
- SN00561532-W 20040409/040407211840 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |